Effect of transforming growth factor-beta1 antisense oligonucleotides on matrix metalloproteinases and their inhibitors in keloid fibroblasts

Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery
Gregor M BranHaneen Sadick

Abstract

To identify changes in the expression of matrixmetalloproteinases (MMPs) and their specific inhibitors tissue inhibitors of metalloproteinases (TIMPs) after targeting of transforming growth factor-beta1 (TGF-beta1) with antisense oligonucleotides. Cross-sectional study. The study was performed on tissue samples from nine patients with keloid scars after otoplasty presenting to the Otolaryngology-Head and Neck Surgery Department of the University Hospital in Mannheim, Germany. Keloid fibroblasts and normal fibroblasts were harvested from auricular keloid scars and healthy skin regions of the same patients during resection procedure of the keloid. Cells were placed in monolayer cultures. Expression of MMPs and TIMPs were analyzed by immunohistochemistry. The effect of TGF-beta1 targeting using antisense oligonucleotides on the expression of both protein groups in keloid-derived fibroblasts was analyzed by enzyme-linked immunosorbent assay and reverse-transcription polymerase chain reaction. Immunohistochemical investigation demonstrated increased expression of MMP-2, -3, -9, and -13 and TIMP-1 and -2. TGF-beta1 antisense therapy significantly down-regulated MMP secretion in vitro. Usage of TGF-beta1 antisense oligodeoxynucleotide...Continue Reading

References

Jul 1, 1996·The British Journal of Dermatology·M VaalamoU K Saarialho-Kere
Oct 1, 1996·Plastic and Reconstructive Surgery·D A BettingerI K Cohen
Feb 5, 1998·Experimental Dermatology·V M Kähäri, U Saarialho-Kere
Jul 27, 1999·Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society·A N NeelyG D Warden
Oct 8, 1999·Plastic and Reconstructive Surgery·F B NiessenM Kon
Nov 11, 1999·Archives of Surgery·A Hernandez, B M Evers
Jan 13, 2000·Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society·C MaN Chegini
Jul 27, 2002·Plastic and Reconstructive Surgery·Thomas A MustoeUNKNOWN International Advisory Panel on Scar Management
Sep 11, 2002·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·O Bock, U Mrowietz
Feb 6, 2004·Experimental Dermatology·Gentaro UchidaKiyonori Harii
Jan 13, 2006·Plastic and Reconstructive Surgery·Ali Al-AttarSteven P Davison
Aug 18, 2006·Current Opinion in Pediatrics·Alison E Slemp, Richard E Kirschner
Jul 31, 2007·International Journal of Surgery·Jagajeevan Jagadeesan, Ardeshir Bayat
Jul 30, 2009·International Journal of Molecular Medicine·Gregor M BranHaneen Sadick

❮ Previous
Next ❯

Citations

Aug 14, 2013·Expert Opinion on Pharmacotherapy·Chenyu Huang, Rei Ogawa
Aug 16, 2011·Journal of the European Academy of Dermatology and Venereology : JEADV·G P Sidgwick, A Bayat
Jun 13, 2020·Frontiers in Cell and Developmental Biology·Grace C LimandjajaSusan Gibbs

❮ Previous
Next ❯

Methods Mentioned

BETA
antisense oligonucleotides
biopsy
enzyme-linked immunosorbent assay
ELISA
PCR
transfect
antisense oligonucleotide

Software Mentioned

R

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.